Patent assignee · DK · COMPANY

Rigshospitalet

16Patents
14Active
16Granted
47Portfolio score

Filing activity: Apr 10, 2000 → Feb 3, 2021 · 4 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US9433589B2 Injectable pharmaceutical compositions comprising adrenaline and citric acid Human Necessities 9 Active
US9573984B2 Chimeric inhibitor molecules of complement activation Emerging Cross-Sectional Technologies 5 Active
US9381243B2 Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof Human Necessities 5 Active
US9381166B2 Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength Physics 3 Active
US10111969B2 uPAR targeting peptide for use in peroperative optical imaging of invasive cancer Human Necessities 3 Active
US8920775B2 Loading technique for preparing radionuclide containing nanoparticles Human Necessities 2 Active
US7807379B2 Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker Physics 2 Active
US7108983B1 Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker Physics 2 Expired
US11554261B2 System for electrical stimulation during functional MRI Human Necessities 1 Active
US12226495B2 18F-labeled novel tetrazines imaging probes for pretargeting in PET imaging Chemistry; Metallurgy 0 Active
US9012154B2 Ficolin-3 assay Physics 0 Active
US10940213B2 Antibody-drug conjugates targeting uPARAP Chemistry; Metallurgy 0 Active
US8580520B2 YKL-40 as a marker for gastrointestinal cancers Physics 0 Active
US7374886B2 Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer Physics 0 Expired
US8697384B2 YKL-40 as a general marker for non-specific disease Physics 0 Active
US11819552B2 Antibody-drug conjugates targeting uPARAP Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.